Literature DB >> 12670525

Common genetic variants of TP53 and BRCA2 in esophageal cancer patients and healthy individuals from low and high risk areas of northern China.

Nan Hu1, Wen-Jun Li, Hua Su, Chaoyu Wang, A M Goldstein, P S Albert, M R Emmert-Buck, Li-Hui Kong, M J Roth, S M Dawsey, Li-Ji He, Shu-Fen Cao, Ti Ding, Carol Giffen, P R Taylor.   

Abstract

TP53 and BRCA2 are frequently mutated in cancer and polymorphisms of these genes may modify cancer risk. We used SSCP and DNA sequencing to assess and compare frequencies of R72P (TP53) and 5'UTR203G>A, N372H, and K1132K (BRCA2) polymorphisms in healthy Chinese subjects at varying risk for esophageal squamous cell carcinoma (ESCC) and in ESCC patients. Suggestive overall differences in the distributions of genotypes by risk groups were seen for all genotypes except K1132K. Differences in R72P and N372H were most likely a reflection of lack of Hardy-Weinberg equilibrium (HWE), however, the difference in 203G>A was due to low prevalence of GG in ESCC patients (0.22 versus 0.36 in high risk group (P=0.047), and 0.22 versus 0.40 in low risk group (P=0.010)), consistent with a disease association. These data suggest that the 203G>A polymorphism in BRCA2 may be associated with risk of ESCC.

Entities:  

Mesh:

Year:  2003        PMID: 12670525     DOI: 10.1016/s0361-090x(03)00031-x

Source DB:  PubMed          Journal:  Cancer Detect Prev        ISSN: 0361-090X


  8 in total

1.  TP53 Arg72Pro polymorphism is associated with esophageal cancer risk: a meta-analysis.

Authors:  De-Ke Jiang; Lei Yao; Wen-Zhang Wang; Bo Peng; Wei-Hua Ren; Xian-Mei Yang; Long Yu
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

2.  Global gene expression profiling and validation in esophageal squamous cell carcinoma and its association with clinical phenotypes.

Authors:  Hua Su; Nan Hu; Howard H Yang; Chaoyu Wang; Mikiko Takikita; Quan-Hong Wang; Carol Giffen; Robert Clifford; Stephen M Hewitt; Jian-Zhong Shou; Alisa M Goldstein; Maxwell P Lee; Philip R Taylor
Journal:  Clin Cancer Res       Date:  2011-03-08       Impact factor: 12.531

3.  Genome-wide loss of heterozygosity and copy number alteration in esophageal squamous cell carcinoma using the Affymetrix GeneChip Mapping 10 K array.

Authors:  Nan Hu; Chaoyu Wang; Ying Hu; Howard H Yang; Li-Hui Kong; Ning Lu; Hua Su; Quan-Hong Wang; Alisa M Goldstein; Kenneth H Buetow; Michael R Emmert-Buck; Philip R Taylor; Maxwell P Lee
Journal:  BMC Genomics       Date:  2006-11-29       Impact factor: 3.969

4.  Association of BRCA2 N372H polymorphism with cancer susceptibility: a comprehensive review and meta-analysis.

Authors:  Wen-Qiong Xue; Yong-Qiao He; Jin-Hong Zhu; Jian-Qun Ma; Jing He; Wei-Hua Jia
Journal:  Sci Rep       Date:  2014-10-28       Impact factor: 4.379

Review 5.  Association between the BRCA2 rs144848 polymorphism and cancer susceptibility: a meta-analysis.

Authors:  Qiuyan Li; Rongwei Guan; Yuandong Qiao; Chang Liu; Ning He; Xuelong Zhang; Xueyuan Jia; Haiming Sun; Jingcui Yu; Lidan Xu
Journal:  Oncotarget       Date:  2017-06-13

Review 6.  Alterations of the TP53 gene in gastric and esophageal carcinogenesis.

Authors:  Marilanda Ferreira Bellini; Aline Cristina Targa Cadamuro; Maysa Succi; Marcela Alcântara Proença; Ana Elizabete Silva
Journal:  J Biomed Biotechnol       Date:  2012-08-07

7.  Implication of BRCA2 -26G>A 5' untranslated region polymorphism in susceptibility to sporadic breast cancer and its modulation by p53 codon 72 Arg>Pro polymorphism.

Authors:  Sailesh Gochhait; Syed Irfan Ahmad Bukhari; Narendra Bairwa; Shivani Vadhera; Katayoon Darvishi; Mohammad Raish; Pawan Gupta; Syed Akhtar Husain; Rameshwar N K Bamezai
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

8.  A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy.

Authors:  Qiuli Liu; Dali Tong; Gaolei Liu; Yuting Yi; Jing Xu; Xingxia Yang; Linang Wang; Jun Zhang; Jin Ye; Yao Zhang; Gang Yuan; Peng Wang; Rongrong Chen; Yanfang Guan; Xin Yi; Dianzheng Zhang; Jun Jiang
Journal:  Cancer Biol Ther       Date:  2018-04-19       Impact factor: 4.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.